Skip to main content

Advertisement

Figure 1 | Journal of Ovarian Research

Figure 1

From: The feasibility and clinical effects of dendritic cell-based immunotherapy targeting synthesized peptides for recurrent ovarian cancer

Figure 1

Frequencies of CD4+ T cells, CD8+T cells, and natural killer cells in patients before and after dendritic cell-based immunotherapy targeting synthesized peptides for recurrent ovarian cancer. (A) Data on frequencies of CD4+ T cells (n = 31), (B) CD8+ T cells (n = 31), and (C) natural killer cells (n = 31) are expressed as a percentage of peripheral blood mononuclear cells.

Back to article page